Fujifilm
ent_21f5454cb84b65a0988d9554
Disclosures
3
Leak Site · 1 jurisdiction
Incidents
—
no linked incident in sample
Max affected reported
—
no filed count in sample
Leak-site claims
3
unverified actor claims
Identity resolution
- Canonical name
- Fujifilm
- Normalized
- fujifilm— dedupe via name-norm; Microsoft / MSFT collapse to one row
- GLEIF LEI
- No match
- SEC EDGAR CIK
- None — not an SEC registrant
- Domain
- fujifilm.com
Unverified threat-actor claim — not a regulatory filing
Attribution, victim identity, and counts shown here derive from a threat actor's public extortion-blog claims, aggregated by ransomware.live. They have not been validated by the victim or any regulator. Treat them as the threat actor's assertion until a regulatory filing or victim disclosure corroborates them.
Disclosure history (3)newest first
- GLOBALLeak Siteas victim2025-08-17
Fujifilm is a globally recognized Japanese multinational corporation known for its innovative contributions to the photography and imaging industry. Founded in 1934, Fujifilm's portfolio now includes products and services in fields such as medical imaging, graphic arts, optical devices, and data storage. With decades of research and technological advancement, the firm continues to influence photography and other industries worldwide.
- GLOBALLeak Siteas victim2025-04-05
Fujifilm has actively promoted the research and development of liposome formulations by harnessing its advanced nano-dispersion technology, analysis technology, and process technology cultivated and evolved through its wide range of product development. In 2017, the company began a U.S. Phase I clinical trial of FF-10832, a liposome-based agent that encapsulates the approved anti-cancer agent gemcitabine *** . In the preclinical mice studies on FF-10850 and FF-10832 *4 Fujifilm has observed the extension of the survival period as a result of immune checkpoint inhibitor *5 combination therapy. In addition, Fujifilm has been promoting the application of liposome for use with next-generation drugs such as nucleic acid drugs and gene therapy drugs. Looking towards future growth, in order to ensure a stable supply of high-quality liposome formulations, Fujifilm is developing a manufacturing facility for producing investigational and commercial drugs through its subsidiary, FUJIFILM Toyama.Geo: Singapore - Leak size: NO DATA 1 pdf - Contains: NO DATA 1 pdf
- GLOBALLeak Siteas victim2021-06-01